| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 | Dec-05-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 8-K | 10-K | 8-K | 10-K | 10-K | 10-K |
| Revenues: |
| Company product sales | 64.3 | 59.6 | | | | | | |
| Company Product | 64.3 | 59.6 | | | | | | |
| Topical | 46.2 | 35.1 | | | | | | |
| Injectables | 18.1 | 24.5 | | | | | | |
| Total revenues [+] | 65.9 | 65.9 | 65.9 | 60.2 | 60.2 | 63.0 | 44.3 | 33.7 |
| Products | | | | | | | 43.5 | 32.1 |
| Net interest income | -21.2 | -12.3 | | -11.2 | | -13.3 | | |
| Revenue growth [+] | 0.0% | 9.4% | 9.4% | -4.5% | | 42.4% | 31.1% | 85.1% |
| Company product sales | 7.9% | | | | | | | |
| Company Product | 7.9% | | | | | | | |
| Topical | 31.4% | | | | | | | |
| Injectables | -25.9% | | | | | | | |
| Contract manufacturing sales | -77.5% | | | | | | | |
| Cost of goods sold | 42.4 | 43.5 | 43.5 | 32.8 | 32.8 | 28.3 | 22.9 | 16.9 |
| Gross profit | 23.5 | 22.4 | 22.4 | 27.4 | 27.4 | 34.7 | 21.3 | 16.8 |
| Gross margin | 35.7% | 34.0% | 34.0% | 45.5% | 45.5% | 55.0% | 48.2% | 49.8% |
| Selling, general and administrative | 20.8 | 23.4 | 23.4 | 19.9 | 19.9 | 15.0 | 11.3 | 6.0 |
| Research and development | 10.8 | 14.1 | 14.1 | 19.3 | 19.3 | 17.1 | 13.2 | 6.9 |
| EBITDA [+] | -1.3 | -9.4 | | -7.2 | | 6.3 | -2.1 | 4.4 |
| EBITDA growth | -86.0% | 31.7% | 28.0% | -213.2% | | -398.4% | -147.7% | 1158.1% |
| EBITDA margin | -2.0% | -14.3% | -22.9% | -11.9% | -19.6% | 10.0% | -4.8% | 13.2% |
| Depreciation | 3.7 | 2.6 | | 1.7 | | 0.9 | 0.6 | 0.4 |
| EBITA | -5.0 | -12.0 | -15.1 | -8.9 | -11.8 | 5.4 | -2.7 | 4.0 |
| EBITA margin | -7.6% | -18.2% | -22.9% | -14.7% | -19.6% | 8.5% | -6.1% | 11.9% |
| Amortization of intangibles | 3.0 | 3.1 | | 2.9 | | 2.8 | 0.5 | 0.1 |
| EBIT [+] | -8.0 | -15.1 | -15.1 | -11.8 | -11.8 | 2.5 | -3.2 | 3.9 |
| EBIT growth | -46.9% | 28.0% | 28.0% | -564.1% | | -179.6% | -181.7% | -4863.4% |
| EBIT margin | -12.2% | -22.9% | -22.9% | -19.6% | -19.6% | 4.0% | -7.2% | 11.6% |
| Interest expense | | | | | | | 13.4 | 0.8 |
| Interest expense | | | | | | | 13.4 | 0.8 |
| Other income (expense), net [+] | -17.0 | -21.2 | -21.2 | -3.5 | -3.5 | -14.2 | 23.3 | 2.3 |
| Gain (loss) on debt retirement | -0.9 | | | | | | | |
| Unrealized gain/loss on derivatives | | | | | | | 23.1 | 2.3 |
| Gain (loss) on foreign currency transactions | -1.5 | -3.4 | | 7.7 | | -0.9 | 0.1 | |
| Other | | | | | 7.7 | | | |
| Pre-tax income | -25.0 | -36.3 | -36.3 | -15.3 | -15.3 | -11.7 | 6.7 | 5.4 |
| Income taxes | 0.1 | -0.1 | 0.0 | -0.1 | -0.1 | 0.3 | 0.0 | 0.2 |
| Tax rate | | 0.2% | 0.0% | 0.6% | 0.6% | | 0.5% | 3.2% |
| Net income | -25.1 | -36.3 | -36.3 | -15.2 | -15.2 | -12.0 | 6.7 | 5.3 |
| Net margin | -38.1% | -55.0% | -55.0% | -25.2% | -25.2% | -19.0% | 15.1% | 15.6% |
| |
| Basic EPS [+] | ($0.47) | ($0.68) | ($0.68) | ($0.28) | ($0.28) | ($0.23) | $0.13 | $0.11 |
| Growth | -31.0% | 137.5% | 137.5% | 26.2% | | -279.0% | 19.6% | -429.5% |
| Diluted EPS [+] | ($0.47) | ($0.68) | ($0.68) | ($0.28) | ($0.28) | ($0.23) | $0.10 | $0.08 |
| Growth | -31.0% | 137.5% | 137.5% | 26.2% | | -327.3% | 21.5% | -355.7% |
| |
| Shares outstanding (basic) [+] | 53.8 | 53.6 | 53.6 | 53.3 | 53.3 | 53.1 | 52.9 | 49.8 |
| Growth | 0.5% | 0.5% | 0.5% | 0.5% | | 0.4% | 6.1% | 14.5% |
| Shares outstanding (diluted) [+] | 53.8 | 53.6 | 53.6 | 53.3 | 53.3 | 53.1 | 67.1 | 64.2 |
| Growth | 0.5% | 0.5% | 0.5% | 0.5% | | -20.9% | 4.5% | 47.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |